Amyloid β, glutamate, excitotoxicity in alzheimer's disease: Are we on the right track?

CNS Neuroscience and Therapeutics

Volumn 19, Issue 8, 2013, Pages 549-555

  Esposito, Zaira ^a   Belli, Lorena ^b   Toniolo, Sofia ^b   Sancesario, Giuseppe ^b   Bianconi, Claudio ^a   Martorana, Alessandro ^b,c  

^a Centro per il Decadimento Cognitivo   (Italy)

^b UNIVERSITY OF ROME TOR VERGATA   (Italy)

^c IRCCS FONDAZIONE SANTA LUCIA   (Italy)

Author keywords

A 42; Alzheimer's disease; Clinical profile; Glutamate; Nicotinic receptor

Indexed keywords

ACETYLCHOLINE; AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN[1-42]; CALCIUM CALMODULIN DEPENDENT PROTEIN KINASE II; CHOLINESTERASE INHIBITOR; DONEPEZIL; GALANTAMINE; GLUTAMIC ACID; MEMANTINE; MITOGEN ACTIVATED PROTEIN KINASE P38; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR 1; N METHYL DEXTRO ASPARTIC ACID RECEPTOR 2A; N METHYL DEXTRO ASPARTIC ACID RECEPTOR 2D; N METHYL DEXTRO ASPARTIC ACID RECEPTOR 3A; N METHYL DEXTRO ASPARTIC ACID RECEPTOR 3B; NICOTINIC RECEPTOR; PLACEBO; POSTSYNAPTIC DENSITY PROTEIN 95; PROTEIN BCL 2; RIVASTIGMINE; UNCLASSIFIED DRUG; VESICULAR GLUTAMATE TRANSPORTER 1; VESICULAR GLUTAMATE TRANSPORTER 2;

ALZHEIMER DISEASE; CELL DEATH; COGNITION; COGNITIVE DEFECT; DEMENTIA; DISEASE SEVERITY; DOWN REGULATION; DRUG EFFICACY; EXCITOTOXICITY; HUMAN; LONG TERM DEPRESSION; LONG TERM POTENTIATION; NERVE CELL NETWORK; NERVE CELL PLASTICITY; NONHUMAN; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SIGNAL TRANSDUCTION; SYNAPTIC TRANSMISSION; TREATMENT DURATION; TREATMENT INDICATION;

AΒ42; ALZHEIMER'S DISEASE; CLINICAL PROFILE; GLUTAMATE; NICOTINIC RECEPTOR;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ANIMALS; CHOLINESTERASE INHIBITORS; EXCITATORY AMINO ACID ANTAGONISTS; GLUTAMIC ACID; HUMANS; RECEPTORS, N-METHYL-D-ASPARTATE;

EID: 84880702377     PISSN: 17555930     EISSN: 17555949     Source Type: Journal    
DOI: 10.1111/cns.12095     Document Type: Review

References (78)

1. Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 2002;297:353-356.
2. Selkoe DJ. Soluble oligomers of the amyloid beta-protein impair synaptic plasticity and behavior. Behav Brain Res 2008;192:106-113.
3. Cheng L, Yin WJ, Zhang JF, Qi JS. Amyloid beta-protein fragments 25-35 and 31-35 potentiate long-term depression in hippocampal CA1 region of rats in vivo. Synapse 2009;63:206-214.
4. Ondrejcak T, Klyubin I, Hu NW, Barry AE, Cullen WK, Rowan MJ. Alzheimer's disease amyloid beta-protein and synaptic function. Neuromolecular Med 2010;12:13-26.
5. Martorana A, Esposito Z, Koch G. Beyond the cholinergic hypothesis: do current drugs work in Alzheimer's disease? CNS Neurosci Ther 2010;16:235-245.
6. Kashani A, Lepicard E, Poirel O, et al. Loss of VGLUT1 and VGLUT2 in the prefrontal cortex is correlated with cognitive decline in Alzheimer disease. Neurobiol Aging 2008;29:1619-1630.
7. Kirvell SL, Esiri M, Francis PT. Down-regulation of vesicular glutamate transporters precedes cell loss and pathology in Alzheimer's disease. J Neurochem 2006;98:939-950.
8. Francis PT. Glutamatergic systems in Alzheimer's disease. Int J Geriatr Psychiatry 2003;18(Suppl 1):S15-S21.
9. Gray CW, Patel AJ. Neurodegeneration mediated by glutamate and beta-amyloid peptide: a comparison and possible interaction. Brain Res 1995;691:169-179.
10. Mattson MP, Cheng B, Davis D, Bryant K, Lieberburg I, Rydel RE. beta-Amyloid peptides destabilize calcium homeostasis and render human cortical neurons vulnerable to excitotoxicity. J Neurosci 1992;12:376-389.
11. Selkoe DJ. Resolving controversies on the path to Alzheimer's therapeutics. Nat Med 2011;17:1060-1065.
12. Ivanov A, Pellegrino C, Rama S, et al. Opposing role of synaptic and extrasynaptic NMDA receptors in regulation of the extracellular signal-regulated kinases (ERK) activity in cultured rat hippocampal neurons. J Neurophysiol 2006;572:789-798.
13. Li S, Jin M, Koeglsperger T, Shepardson NE, Shankar GM, Selkoe DJ. Soluble A(beta) oligomers inhibit long term potentiation through a mechanism involving excessive activation of extrasynaptic NR2B-containing NMDA receptors. J Neurosci 2011;31:6627-6638.
14. Palop JJ, Mucke L. Amyloid-beta-induced neuronal dysfunction in Alzheimer's disease: from synapses toward neural networks. Nat Neurosci 2010;13:812-818.
15. Danysz W, Parsons GC. Alzheimer's disease, beta amyloid, glutamate, NMDA receptors and memantine. Br J Pharm 2012;167:324-352.
16. Koch G, Di Lorenzo F, Bonnì S, Ponzo V, Caltagirone C, Martorana A. Impaired LTP- but not LTD-Like Cortical Plasticity in Alzheimer's Disease Patients. J Alzheimers Dis 2013;33:525-533.
17. Texidó L, Martín-Satué M, Alberdi E, Solsona C, Matute C. Amyloid β peptide oligomers directly activate NMDA receptors. Cell Calcium 2011;49:184-190.
18. Domingues A, Almeida S, da Cruz e Silva EF, Oliveira CR, Rego AC. Toxicity of beta-amyloid in HEK293 cells expressing NR1/NR2A or NR1/NR2B N-methyl-d-aspartate receptor subunits. Neurochem Int 2007;50:872-880.
19. Rammes G, Hasenjäger A, Sroka-Saidi K, Deussing JM, Parsons CG. Therapeutic significance of NR2B-containing NMDA receptors and mGluR5 metabotropic glutamate receptors in mediating the synaptotoxic effects of β-amyloid oligomers on long-term potentiation (LTP) in murine hippocampal slices. Neuropharmacology 2011;60:982-990.
20. Kerven M, Angeli A, Nicole O, et al. Selective impairment of some forms of synaptic plasticity by oligomeric amyloid beta peptide in the mouse hippocampus: implication of extrasynaptic NMDA receptors. J Alzheimer Dis 2012;32:183-196.
21. Bordji K, Becerill-Ortega J, Nicole O, Buisson A. Activation of extrasynaptic, but not synaptic, NMDA receptors modifies amyloid precursor protein expression pattern and increases amyloid-Beta production. J Neurosci 2010;30:15927-15942.
22. Wang Q, Walsh DM, Rowan MJ, Selkoe DJ, Anwyl R. Block of long term potentiation by naturally secreted and synthetic amyloid-beta peptide in hippocampal slices is mediated via activation of the kinases c-Jun N-terminal kinase, cyclin-dependent kinase 5, and p38 mitogen-activated protein kinase as well as metabotropic glutamate receptor type 5. J Neurosci 2004;24:3370-3378.
23. Hardingham GE, Fukunaga Y, Banding H. Extrasynaptic NMDARs oppose synaptic NMDARs by triggering CREB shut-off and cell death pathways. Nat Neurosci 2002;5:405-414.
24. Koffie RM, Hyman BT, Spires-Jones TL. Alzheimer's disease: synapses gone cold. Mol Neurodeg 2012;6:63.
25. Parsons CG, Stöffler A, Danysz W. Memantine: a NMDA receptor antagonist that improves memory by restoration of homeostasis in the glutamatergic system-too little activation is bad, too much is even worse. Neuropharmacology 2007;53:699-723.
26. Koch G, Di Lorenzo F, Bonnì S, Ponzo V, Caltagirone C, Martorana A. Impaired LTP- but not LTD-like cortical plasticity in Alzheimer's disease patients. J Alzheimers Dis 2012;31:593-599.
27. Battaglia F, Wang HY, Ghilardi MF, et al. Cortical plasticity in Alzheimer's disease in humans and rodents. Biol Psychiatry 2007;62:1405-1412.
28. Burke SN, Barnes CA. Senescent synapses and hippocampal circuit dynamics. Trends Neurosci 2010;33:153-161.
29. Giacobini E. Cholinergic function and Alzheimer's disease. Int J Geriatr Psychiatry 2003;18(Suppl 1):S1-S5.
30. Selkoe DJ. Defining molecular targets to prevent Alzheimer disease. Arch Neurol 2005;62:192-195.
31. Sattelle DB, Buckingham SD, Akamatsu M, et al. Comparative pharmacology and computational modelling yield insights into allosteric modulation of human alpha7 nicotinic acetylcholine receptors. Biochem Pharmacol 2009;78:836-843.
32. Kar S, Slowikowski SP, Westaway D, Mount HT. Interactions between beta-amyloid and central cholinergic neurons: implications for Alzheimer's disease. J Psychiatry Neurosci 2004;29:427-441.
33. McKay BE, Placzek AN, Dani JA. Regulation of synaptic transmission and plasticity by neuronal nicotinic acetylcholine receptors. Biochem Pharmacol 2007;74:1120-1123.
34. Gray R, Rajan AS, Radcliffe KA, Yakehiro M, Dani JA. Hippocampal synaptic transmission enhanced by low concentrations of nicotine. Nature 1996;383:713-716.
35. Jürgensen S, Ferreira ST. Nicotinic receptors, amyloid-beta, and synaptic failure in Alzheimer's disease. J Mol Neurosci 2010;40:221-229.
36. Liu Q, Huang Y, Xue F, et al. A novel nicotinic acetylcholine receptor subtype in basal forebrain cholinergic neurons with high sensitivity to amyloid peptides. J Neurosci 2009;29:918-929.
37. Ni R, Marutle A, Nordberg A. Modulation of α7 Nicotinic Acetylcholine Receptor and Fibrillar Amyloid-β Interactions in Alzheimer's Disease Brain. J Alzheimers Dis 2013;33:841-851.
38. Revett TJ, Baker GB, Jhamandas J, Kar S. Glutamate system, amyloid ß peptides and tau protein: functional interrelationships and relevance to Alzheimer disease pathology. J Psychiatry Neurosci 2013;38:6-23.
39. Zimmer ER, Kalinine E, Haas CB, et al. Pretreatment with memantine prevents Alzheimer-like alterations induced by intrahippocampal okadaic acid administration in rats. Curr Alzheimer Res, 2012;9:1182-1190.
40. Nimmrich V, Reymann KG, Strassburger M, et al. Inhibition of calpain prevents NMDA-induced cell death and beta-amyloid-induced synaptic dysfunction in hippocampal slice cultures. Br J Pharmacol 2010;159:1523-1531.
41. Okamoto S, Pouladi MA, Talantova M, et al. Balance between synaptic versus extrasynaptic NMDA receptor activity influences inclusions and neurotoxicity of mutant huntingtin. Nat Med 2009;15:1407-1413.
42. Xia P, Chen HS, Zhang D, Lipton SA. Memantine preferentially blocks extrasynaptic over synaptic NMDA receptor currents in hippocampal autapses. J Neurosci 2010;30:11246-11250.
43. Klyubin I, Wang Q, Reed MN, et al. Protection against Abeta-mediated rapid disruption of synaptic plasticity and memory by memantine. Neurobiol Aging 2011;32:614-623.
44. Song MS, Rauw G, Baker GB, Kar S. Memantine protects rat cortical cultured neurons against beta-amyloid-induced toxicity by attenuating tau phosphorylation. Eur J Neurosci 2008;28:1989-2002.
45. Lacor PN, Buniel MC, Furlow PW, et al. Abeta oligomer-induced aberrations in synapse composition, shape, and density provide a molecular basis for loss of connectivity in Alzheimer's disease. J Neurosci 2007;27:796-807.
46. Lambert MP, Barlow AK, Chromy BA, et al. Diffusible, nonfibrillar ligands derived from Abeta (1-42) are potent central nervous system neurotoxins. Proc Natl Acad Sci USA 1998;95:6448-6453.
47. Zhao X, Marszalec W, Toth PT, Huang J, Yeh JZ, Narahashi T. In vitro galantamine-memantine co-application: mechanism of beneficial action. Neuropharmacology 2006;51:1181-1191.
48. Grossberg GT, Edwards KR, Zhao Q. Rationale for combination therapy with galantamine and memantine in Alzheimer's disease. J Clin Pharmacol 2006;46(Suppl 1):17S-26S.
49. Farrimond LE, Roberts E, McShane R. Memantine and cholinesterase inhibitor combination therapy for Alzheimer's disease: a systematic review. BMJ Open 2012;2:e000917.
50. Lorrio S, Negredo P, Roda JM, García AG, López MG. Effects of memantine and galantamine given separately or in association, on memory and hippocampal neuronal loss after transient global cerebral ischemia in gerbils. Brain Res 2009;1254:128-137.
51. Csernansky JG, Bardgett ME, Sheline YI, Morris JC, Olney JW. CSF excitatory amino acids and severity of illness in Alzheimer's disease. Neurology 1996;46:1715-1720.
52. Simoni E, Daniele S, Bottegoni G, et al. Combining Galantamine and Memantine in Multitargeted. New Chemical Entities Potentially Useful in Alzheimer's Disease. J Med Chem, 2012;55:9708-9721.
53. Winblad B, Poritis N. Memantine in severe dementia: results of the 9M-Best Study (Benefit and efficacy in severely demented patients during treatment with memantine). Int J Geriatr Psychiatry 1999;14:135-146.
54. Reisberg B, Doody R, Stöffler A, Schmitt F, Ferris S, Möbius HJ. Memantine in moderate-to-severe Alzheimer's disease. N Engl J Med 2003;348:1333-1341.
55. Atri A, Shaughnessy LW, Locascio JJ, Growdon JH. Long-term course and effectiveness of combination therapy in Alzheimer disease. Alzheimer Dis Assoc Disord 2008;22:209-221.
56. Porsteinsson AP, Grossberg GT, Mintzer J, Olin JT, Memantine MEM-MD-12 Study Group. Memantine treatment in patients with mild to moderate Alzheimer's disease already receiving a cholinesterase inhibitor: a randomized, double-blind, placebo-controlled trial. Curr Alzheimer Res 2008;5:83-89.
57. Periclou AP, Ventura D, Sherman T, Rao N, Abramowitz WT. Lack of pharmacokinetic or pharmacodynamic interaction between memantine and donepezil. Ann Pharmacother 2004;38:1389-1394.
58. Howard R, McShane R, Lindesay J, et al. Donepezil and memantine for moderate-to-severe Alzheimer's disease. N Engl J Med 2012;366:893-903.
59. Burke D, ACP Journal Club. Donepezil or memantine improved cognitive functioning in moderate-to-severe Alzheimer disease. Ann Intern Med 2012;156:JC6-JC10.
60. Peskind ER, Potkin SG, Pomara N, et al. Memantine treatment in mild to moderate Alzheimer disease: a 24-week randomized, controlled trial. Am J Geriatr Psychiatry 2006;14:704-715.
61. Bakchine S, Loft H. Memantine treatment in patients with mild to moderate Alzheimer's disease: results of a randomised, double-blind, placebo-controlled 6-month study. J Alzheimers Dis 2008;13:97-107.
62. McShane R, Areosa Sastre A, Minakaran N. Memantine for dementia. Cochrane Database Syst Rev 2006;19:CD003154.
63. Cummings JL, Schneider E, Tariot PN, Graham SM, Memantine MEM-MD-02 Study Group. Behavioral effects of memantine in Alzheimer disease patients receiving donepezil treatment. Neurology 2006;67:57-63.
64. Martorana A, Semprini R, Koch G. Clinical Profile of Alzheimer's Disease Non-Responder Patient, Advanced Understanding of Neurodegenerative Diseases, Raymond Chuen-Chung Chang (Ed.), ISBN: 978-953-307-529-7, InTech. 2011.
65. Wallin AK, Blennow K, Zetterberg H, Londos E, Minthon L, Hansson O. CSF biomarkers predict a more malignant outcome in Alzheimer disease. Neurology 2010;74:1531-1537.
66. Andreasen N, Minthon L, Davidsson P, et al. Evaluation of CSF-tau and CSF-Abeta42 as diagnostic markers for Alzheimer disease in clinical practice. Arch Neurol 2001;58:373-379.
67. Van der Vlies AE, Verwey NA, Bouwman FH, et al. CSF biomarkers in relationship to cognitive profiles in Alzheimer disease. Neurology 2009;72:1056-1061.
68. Blennow K, Hampel H. CSF markers for incipient Alzheimer's disease. Lancet Neurol 2003;2:605-613.
69. Hampel H, Broich K. Enrichment of MCI and early Alzheimer's disease treatment trials using neurochemical and imaging candidate biomarkers. J Nutr Health Aging 2009;13:373-375.
70. Vlachos GS, Paraskevas GP, Naoumis D, Kapaki E. Cerebrospinal fluid β-amyloid 1-42 correlates with rate of progression in Alzheimer's disease. J Neural Transm 2012;119:799-804.
71. Rabinovici GD, Jagust WJ. Amyloid imaging in aging and dementia: testing the amyloid hypothesis in vivo. Behav Neurol 2009;21:117-128.
72. Rabinovici GD, Furst AJ, Alkalay A, et al. Increased metabolic vulnerability in early-onset Alzheimer's disease is not related to amyloid burden. Brain 2010;133:512-528.
73. Jack CR Jr, Wiste HJ, Vemuri P, et al. Alzheimer's Disease Neuroimaging Initiative. Brain beta-amyloid measures and magnetic resonance imaging atrophy both predict time-to-progression from mild cognitive impairment to Alzheimer's disease. Brain 2010;133:3336-3348.
74. Tang YP, Shimizu E, Dube GR, et al. Genetic enhancement of learning and memory in mice. Nature 1999;401:63-69.
75. Magnusson KR, Nelson SE, Young AB. Age-related changes in the protein expression of sub units of the NMDA receptor. Brain Res Mol Brain Res 2002;99:40-45.
76. Magnusson KR, Scruggs B, Zhao X, Hammersmark R. Age-related declines in a two-day reference memory task are associated with changes in NMDA receptor subunits in mice. BMC Neurosci 2007;8:43.
77. Zhao X, Rosenke R, Kronemann D, et al. The effects of aging on N-methyl-d-aspartate receptor subunits in the synaptic membrane and relationships to long-term spatial memory. Neuroscience 2009;162:933-945.
78. Cao X, Cui Z, Feng R, et al. Maintenance of superior learning and memory function in NR2B transgenic mice during ageing. Eur J Neurosci 2007;25:1815-1822.